-
(S)-Mephenytoin: CYP2C19 Substrate Workflows in Organoid PK
2026-05-15
(S)-Mephenytoin is the benchmark CYP2C19 substrate for high-fidelity drug metabolism studies in advanced in vitro models, including hiPSC-derived intestinal organoids. Learn how to optimize protocols, troubleshoot common pitfalls, and leverage the latest organoid technologies for translational pharmacokinetic insights.
-
HDAC8-Mediated AKT Activation Drives Resistance to MEK1/2 In
2026-05-15
This study elucidates how histone deacetylase 8 (HDAC8) enables cancer cells to resist MEK1/2 inhibition by activating AKT via upregulation of PLCB1 and suppression of DESC1. These findings highlight novel molecular targets to overcome resistance in cancers harboring NRAS/BRAF mutations.
-
Ampicillin sodium (A2510): Data-Driven Solutions for Assays
2026-05-14
This article addresses routine challenges in cell viability and antibacterial activity assays, guiding biomedical researchers through best practices, protocol optimization, and product reliability for Ampicillin sodium (SKU A2510). Leveraging peer-reviewed evidence and real-world lab scenarios, the content highlights how Ampicillin sodium underpins reproducible bacterial cell wall biosynthesis inhibition workflows and offers direct links to validated protocols and product data.
-
Vitamin C-Induced Non-Apoptotic Cell Death in Osteosarcoma
2026-05-14
This study demonstrates that pharmacological, redox-active vitamin C triggers non-apoptotic cell death in human osteosarcoma via orchestrated intracellular ROS-iron–calcium signaling and mitochondrial dysfunction. The findings reveal a unique cytotoxic pathway in cancer cells, informing future research on metabolic vulnerabilities in osteosarcoma.
-
EdU Imaging Kits (HF594): Reliable S-Phase DNA Synthesis Ass
2026-05-13
EdU Imaging Kits (HF594) address critical challenges in cell proliferation assays by enabling sensitive, artifact-free measurement of DNA synthesis during S-phase. This product is suitable for researchers requiring robust quantification of proliferating cells in microscopy and flow cytometry applications. It is not intended for live cell imaging or settings where copper-catalyzed chemistry is incompatible with downstream protocols.
-
Polyphyllin H Reverses Paclitaxel Resistance via Cholesterol
2026-05-13
Ye et al. (2025) demonstrate that Polyphyllin H disrupts membrane cholesterol to inhibit ABCB1 and ABCC3, effectively reversing paclitaxel resistance in breast cancer cells. Their multi-target, cholesterol-centric strategy outperforms single-transporter inhibitors and suggests a translational framework for overcoming multidrug resistance in oncology.
-
Atorvastatin (SKU C6405): Reliable Benchmarks for Cell & Vas
2026-05-12
This article addresses real-world laboratory challenges in cholesterol metabolism, vascular cell biology, and ferroptosis-driven oncology research, centering on Atorvastatin (SKU C6405) from APExBIO. By focusing on scenario-driven Q&A, it demonstrates how Atorvastatin delivers reproducible, quantitatively validated results in cell viability and disease models, offering practical protocol guidance for researchers.
-
Clozapine N-oxide: Precision Chemogenetics for Neuronal Modu
2026-05-12
Clozapine N-oxide (CNO) is the gold-standard chemogenetic actuator enabling precise, reversible modulation of neuronal activity in vivo and in vitro. With proven specificity for DREADDs and robust data on 5-HT2 receptor density reduction, CNO from APExBIO empowers neuroscience researchers to dissect neural circuits with unmatched reproducibility and control.
-
Cisplatin (CDDP) in Cancer Research: Optimizing Experimental
2026-05-11
Cisplatin (CDDP) remains the gold-standard DNA crosslinking agent for cancer research, offering robust and reproducible apoptosis induction and chemoresistance modeling. This article delivers actionable protocol enhancements, advanced troubleshooting strategies, and a synthesis of new clinical insights to empower translational oncology studies.
-
Ferroptosis-Gene Signature and Atorvastatin in HCC Prognosis
2026-05-11
This study introduces a novel four-gene ferroptosis-related prognostic model for hepatocellular carcinoma (HCC) and provides experimental evidence that atorvastatin can induce ferroptosis in HCC cells. The findings offer new biomarkers for risk stratification and highlight a mechanistic link between HMG-CoA reductase inhibition and ferroptosis-based cancer therapy.
-
Caspase-3 Colorimetric Assay Kit: Protocol, QC, and Troubles
2026-05-10
The Caspase-3 Colorimetric Assay Kit addresses the need for rapid, sensitive, and quantitative measurement of DEVD-dependent caspase-3 activity. It is best deployed for apoptosis assays, caspase signaling pathway studies, and biomarker quantification in neurodegenerative and cell death research. The kit is not suitable for mechanistic claims outside these contexts or for direct in vivo diagnostics.
-
Protein A/G Magnetic Beads: Technical Guide for Antibody Wor
2026-05-09
Protein A/G Magnetic Beads provide efficient, low-background purification of IgG antibodies and associated complexes from complex samples, supporting high-specificity immunoprecipitation and protein-protein interaction analysis. They are ideal for workflows requiring stringent Fc-specific binding but should not be used for diagnostic or medical applications, or where binding to non-IgG is required.
-
Reelin Signaling as a Prerequisite for Ketamine’s Antidepres
2026-05-08
This study uncovers that intact synaptic Reelin signaling is essential for ketamine to induce both synaptic plasticity and behavioral antidepressant effects in mouse models. The findings inform why approximately half of treatment-resistant depression patients do not respond to ketamine and highlight molecular targets for improving therapeutic strategies.
-
Protease Inhibitor Cocktail (EDTA-Free, 100X in DMSO): Pract
2026-05-08
The Protease Inhibitor Cocktail (EDTA-Free, 100X in DMSO) prevents unwanted proteolysis during protein extraction and sample preparation, particularly for workflows sensitive to divalent cation chelation. It is not recommended for applications where EDTA-based inhibition is essential or in protocols incompatible with DMSO.
-
Busulfan: DNA Alkylating Agent for Senescence & Germ Cell Mo
2026-05-07
Busulfan’s DNA alkylating action drives rigorous modeling of senescence in WI38 fibroblasts and targeted germ cell depletion in mice. This article translates cutting-edge dual recombinase genetic tracing evidence into actionable protocols, workflow enhancements, and troubleshooting strategies for maximizing reproducibility with APExBIO’s Busulfan.